Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS)
Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS)
复制标题
DOI：
10.1111/dom.13810
复制
发表时间：
2019-07-05
影响因子：
5.8
通讯作者：
Laimer, Markus
中科院分区：
文献类型：
--
作者：
Melmer, Andreas;Zuger, Thomas;Laimer, Markus
开放源码人工胰腺系统(OpenAPS)已经在糖尿病社区获得了相当大的兴趣。我们分析了80名患有1型糖尿病(T1D)的OpenAPS用户的连续血糖监测(CGM)记录。总共有19495天(53.4年)的CGM记录。平均血糖为7.6+/-1.1 mmoL/L，时间在3.9-10 mmoL/L为77.5+/-10.5%，13.9 mmoL/L为4.1+/-4.0%。在34名OpenAPS用户中，在使用传感器增强泵疗法(SAP)时获得了额外的CGM记录。SAP转为OpenAPS后，平均血糖较低(-0.0001±0.7；P<；0.0001)，估计糖化血红蛋白较低(-0.4+/-0.5%；P<；0.0001)，较高的时间在3.9-10 mmoL/L(+9.3+/-9.5%；p<；0.0001)，较短的时间&3.0 mmo1/L(-0.7+/-2.2%；P=0.0171)，较低的变异系数(-2.4+/-5.8；P=0.0198)和较低的日均差(-0.6+/-0.9 mm ol/L；P=0.0005)。使用OpenAPS的血糖控制与更严格开发和测试的AP系统的结果相当。然而，OpenAPS被高度选择性、积极性和技术熟练的队列使用，尽管没有被批准用于治疗T1D患者。
Open source artificial pancreas systems (OpenAPS) have gained considerable interest in the diabetes community. We analyzed continuous glucose monitoring (CGM) records of 80 OpenAPS users with type 1 diabetes (T1D). A total of 19 495 days (53.4 years) of CGM records were available. Mean glucose was 7.6 +/- 1.1 mmol/L, time in range 3.9-10 mmol/L was 77.5 +/- 10.5%, 13.9 mmol/L was 4.1 +/- 4.0%, respectively. In 34 OpenAPS users, additional CGM records were obtained while using sensor-augmented pump therapy (SAP). After changing from SAP to OpenAPS, lower mean glucose (-0.6 +/- 0.7; P < 0.0001), lower estimated HbA1c (-0.4 +/- 0.5%; P < 0.0001), higher time in range 3.9-10 mmol/L (+9.3 +/- 9.5%; P < 0.0001), less time < 3.0 mmol/L (-0.7 +/- 2.2%; P = 0.0171), lower coefficient of variation (-2.4 +/- 5.8; P = 0.0198) and lower mean of daily differences (-0.6 +/- 0.9 mmol/L; P = 0.0005) was observed. Glycaemic control using OpenAPS was comparable with results of more rigorously developed and tested AP systems. However, OpenAPS was used by a highly selective, motivated and technology-adept cohort, despite not being approved for the treatment of individuals with T1D.